Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
VEGFR2/KDR/Flk-1 Antibody (20I6), Janelia Fluor™ 549, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP118646JF549
Description
VEGFR2/KDR/Flk-1 Monoclonal specifically detects VEGFR2/KDR/Flk-1 in Human samples. It is validated for Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Frozen.Specifications
VEGFR2/KDR/Flk-1 | |
Monoclonal | |
Janelia Fluor 549 | |
50mM Sodium Borate with 0.05% Sodium Azide | |
KDR | |
Recombinant human soluble extracellular KDR (D7) | |
0.1 mL | |
Primary | |
The monoclonal antibody will detect native human VEGFR-2/KDR in ELISA experiments and on the surface of different human cell types. | |
Store at 4°C in the dark. | |
IgG1 |
Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Frozen) | |
20I6 | |
Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Frozen | |
CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, FLK1tyrosine kinase growth factor receptor, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGFR, VEGFR2, VEGFR-2 | |
Mouse | |
Protein G purified | |
Angiogenesis, Apoptosis, Cancer, Cellular Markers, Cytoskeleton Markers, Endothelial Cell Markers, Hematopoietic Stem Cell Markers, HIF Target Genes, Hypoxia, Signal Transduction, Stem Cell Markers, Tumor Suppressors, Tyrosine Kinases | |
3791 | |
Human | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction